Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

Sales of the vaccine have been declining due to weak demand trends in China amid an economic slowdown. Gardasil sales ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

Merck announced yesterday that the US Food and Drug Administration (FDA) has approved its monoclonal antibody vaccine ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

In a Phase 3 test that compared Enflonsia to Synagis, the safety of the Merck drug was comparable to the AstraZeneca product. Pfizer’s presence in RSV is through Abrysvo, a vaccine comprised of ...

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

(Reuters) -Shares of global vaccine makers were mixed on Tuesday, as investors assessed U.S. Health Secretary Robert F.